Navigation Links
Henry Ford Hospital study: Fewer infections with new heart-pump implant
Date:5/27/2010

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

Known as a left ventricular assist device, the newest version of the HeartMate is much smaller than the first and uses a tiny turbine with synthetic ruby bearings, lubricated by the blood itself, to continually push blood through the body. Its predecessor is larger, heavier, has more moving parts, and is designed to mimic the pulsing of blood through a healthy heart.

Implanting the latest version of the pump is also less invasive, so researchers at the Henry Ford Heart & Vascular Institute sought to find whether it offered less risk of infection.

"Left ventricular assist devices have become the standard of care for patients with end-stage heart failure," says lead author Jeffrey A. Morgan, M.D. Associate Director of Circulatory Assist Device Program and Cardiac Transplantation, at Henry Ford. "However, development of a device-related infection can be a source of significant morbidity and mortality.

"The HeartMate II was designed to address specific limitations of the HM I, including minimizing the invasiveness of LVAD implantation. The focus of this study was to ascertain whether the HeartMate II was associated with a decreased incidence of device-related infections."

The study will be presented May 27 at the American Society for Artificial Internal Organs in Baltimore.

The study, which ran from March 2006 through June 2009, included 58 patients with chronic heart failure who were implanted with either the HeartMate II which the U.S. Food and Drug Administration approved in January for use in patients with severe heart failure who are not candidates for a heart transplant or its predecessor, the larger and more complicated HeartMate I XVE.

.

Of the study group, 41 patients were implanted with the HeartMate II and 17 with the older model. Those who developed infections were treated with antibiotics, and the effects of those infections on their short- and long-term survival were also studied.

Two patients, or 4.9 percent of those who had HeartMate II pumps, developed infections, compared to four patients, or 23.5 percent of those whose hearts were assisted by the previous model. The researchers also found no significant difference in survival between HM II patients with and without infection at 30 days and one year.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Henry Ford Hospital: New left-side heart pump improves right-side heart function
2. Henry Ford Hospital study: Less prep needed for colonoscopy
3. Henry Ford Health System goes radical: Creating the hospital of the future
4. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
5. Henry Ford Hospital study: Shoulder function not fully restored after surgery
6. Henry Ford Hospital study shows link between vitamin D, skin cancer
7. Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus
8. National Press Club to Host NEWSMAKER Media Briefing on Cornhusker Kickback With South Carolina Attorney General Henry McMaster
9. iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems
10. Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame
11. Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... MA (PRWEB) , ... May 02, 2016 , ... Pregnancy ... tips when trying to conceive. , “If you are ready to have ... Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company ... automate and improve the rapid diagnosis, triage and admission of patients leveraging IBM ... and mobile experience for the first time at GENBAND’s Perspectives16 conference. , ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Model Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate ... provider-administered drugs while preserving care provided to beneficiaries. The webinar will review the details ...
(Date:5/2/2016)... , ... May 02, 2016 , ... For many artists, ... artist Curt Walter has developed it into a science. , Using the new, ... achieve subtly differentiated shades that add depth and meaning to his works. What’s more, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: